GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or metastatic solid tumors (including but not limited to head and neck cancer, malignant melanoma, CRC, renal cell carcinoma, cervical cancer, and breast cancer). Study details include:

Trial Details

NCT ID
NCT06265025
Phase
PHASE1 / PHASE2
Sponsor
GeneMedicine Co., Ltd.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • GM103 (Part A)
  • GM103 (Part B)
  • GM103 and Pembrolizumab (Part C)
Locations (sample)
  • Goyang-si, Gyeonggi-do, South Korea|37.65639,126.835
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Patient must be 18 years of age or over, at the time of signing the informed consent.
  • Have a diagnosis of locally advanced, unresectable, refractory and/or metastatic solid tumors
  • Have a tumor that is accessible and is willing to consent to tumor biopsies during the study.
  • Have at least one measurable site of disease according to RECIST 1.1 criteria; The lesions should be either previously non irradiated or progressiv…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →